Results 161 to 170 of about 1,087,298 (289)
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang +3 more
wiley +1 more source
Inactivation of Ebola, Nipah, and Lassa viruses in tissue using neutral buffered formalin, MagMAX lysis/binding solution, or TriPure isolation reagent. [PDF]
Davies KA +4 more
europepmc +1 more source
PANCREATIC ELASTASE: PURIFICATION, PROPERTIES, AND FUNCTION
UrbanJ. Lewis +2 more
openalex +1 more source
Purification and properties of Bacteroides heparinolyticus heparinase (heparin lyase, EC 4.2.2.7) [PDF]
T. Nakamura +2 more
openalex +1 more source
Tumor mutational burden as a determinant of metastatic dissemination patterns
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal +4 more
wiley +1 more source
Innovative Membrane Purification of Plant-Based Lipase from Flaxseed Using Graphene Oxide. [PDF]
do Nascimento NN +3 more
europepmc +1 more source
Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunity
Von Locquenghien et al. report that MiTE‐144, a triggering receptor expressed on myeloid cells 2 (TREM2) blocking antibody fused to interleukin‐2 (IL2) variant with tumour microenvironment restricted activation, demonstrates superior anticancer efficiency in a preclinical setting.
Isaure Vanmeerbeek +2 more
wiley +1 more source

